Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

NCT00826449 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer
Non-Small Cell Lung Cancer

Interventions

DRUG: Dasatinib
DRUG: Erlotinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]